Various agents were described to inhibit YY1 and restore RKIP expression, including small molecules, peptides, RNA-based therapeutics, and gene editing tools that re-sensitize tumors to immunotherapy, and suppress tumor-promoting signaling pathways. The gene discussed is PEBP1; the disease is neoplasm.